#LoveYourLiver this January. This month, we are taking a closer look at Liver Cirrhosis.
Liver cirrhosis occurs when the healthy tissue of the liver is replaced with scar tissue (fibrosis) due to long-term liver damage. Liver cirrhosis can result in liver failure which can be fatal.
Liver complications such as liver disease and cirrhosis can be detrimental if it is not treated or monitored. Liver disease is the only major cause of death still increasing year-on-year. Globally, deaths due to liver cirrhosis have increased from 676,000 in 1980 to over 1 million in 2010 (NCBI, 2014). Cirrhosis and other chronic liver diseases have increased by 12.4% from 2006-2016 and was the cause of 1,256,900 deaths in 2016 (Global Burden of Disease, 2016).
There are a few factors that increase the risk of liver cirrhosis. The three main factors are heavy alcohol consumption, an undiagnosed hepatitis infection, particularly hepatitis C, and non-alcoholic steatohepatitis (a more severe form of non-alcoholic fatty liver disease) due to obesity.
There are numerous symptoms associated with liver cirrhosis. Some of the more severe symptoms include:
- Jaundice – yellowing of the skin and whites of the eyes
- Personality changes, confusion, difficulty concentrating, memory loss, or hallucinations
- A tendency to bleed or bruise easily
- In women, abnormal periods
- In men, enlarged breasts, a swollen scrotum (the loose sac of skin that contains the testicles) or shrunken testicles
- Stomach pain – swollen or bloated stomach
Liver cirrhosis cannot be cured, but the aim of treatment is to manage the symptoms and complications, and to stop the condition getting worse.
#LoveYourLiver and prevent or reduce the symptoms of liver cirrhosis through: moderating alcohol consumption, not sharing needles to inject drugs, using a condom during sex, taking medications as prescribed, and maintaining a healthy weight.
The early stages of liver cirrhosis usually does not present any symptoms and is often first detected using routine blood tests. Liver cirrhosis can be diagnosed and monitored through the following routine blood tests:
Alanine Aminotransferase (ALT)
ALT is one of the enzymes within the aminotransferases group and are among the most sensitive liver enzymes. The normal concentration levels of ALT in the blood are low, however, when the liver is damaged, such as liver cirrhosis, the levels of ALT increase. During the diagnosis of liver cirrhosis, the root cause of the damage can be established, such as disease, drug or injury. ALT is commonly measured alongside AST as part of the hepatic panel.
Aspartate Aminotransferase (AST)
AST is an enzyme found throughout the body. Elevated concentration levels of AST in the blood is directly correlated to the severity of the tissue damage. AST also allows for the root cause of the damage to be diagnosed. Excessive levels are indicative of damage due to acetaminophen overdose or acute viral hepatitis. Moderately high levels are indicative of alcohol abuse. Slightly high levels are indicative of cirrhosis.
AST is commonly measured alongside ALT as part of the hepatic panel, although ALT levels are higher in most types of liver damage.
Albumin is a special protein made in the liver and provides the body with the proteins it requires to grow and repair tissue. The body requires a proper balance of albumin to prevent fluid from seeping out of blood vessels. Decreased concentrations levels of this protein in the blood is an indicator of liver cirrhosis.
Randox supply a range of third party clinical diagnostic hepatic reagents to aid in the diagnosis and managing the complications of liver cirrhosis. All reagents are available for use on a range of third party biochemistry analysers. Randox offer the following hepatic reagents to diagnose liver cirrhosis:
Randox also offer the following high performance and unique tests to diagnose liver cirrhosis:
Why choose Randox reagents?
- Randox offers the largest range of chemistries
- Liquid ready-to-use reagents available
- Automated applications for a wide range of clinical analysers
- Excellent correlation to reference methods
- Wide measuring ranges
- Flexible pack sizes
- Official accreditation to national and international standards including UKAS, ISO 13485:2003, and FDA.
- Easy fit reagents
- Easy read reagents
To request an application for your specific analyser, contact email@example.com
For more information on liver function or to view our hepatic panel, visit https://www.randox.com/liverfunction/
This week the RX series team celebrate Diabetes Awareness Week. This is an annual event in the UK calendar, giving public the chance to raise as much awareness as possible for the condition and get involved with taking preventative action.
Diabetes is a chronic disease which causes a person’s blood sugar level to become too high. Since 1996, the number of people diagnosed with diabetes in the UK has risen from 1.4 million to 3.5 million. Of these, about 270,000 have type 2 diabetes and around 300,000 have type 1 diabetes. ₁
Diabetes prevalence in the UK is likely to rise to 5 million by 2025, therefore if we know our risks and are aware of symptoms, we can do something about this staggering figure. Certain risks associated with diabetes include age, family history, high blood pressure and being overweight. As this disease continues to challenge healthcare today it is important we take action on Diabetes Awareness Week.
Signs and symptoms of diabetes include unexplained weight loss, frequent urination, tiredness and lack of energy, excessive thirst, blurred vision, tingling sensation/numbness in the hands or feet and slow-healing wounds.
Whilst the condition cannot be cured, it is treatable and can be managed and controlled with different treatments to suit different people. There are several assays that Randox have developed to monitor and diagnose diabetes. These include; Fructosamine, Glucose and HbA1c. Monitoring diabetes is hugely important to ensure that you are safe from complications.
The RX series includes a vast Diabetes test Panel.
#DiabetesAwarenessWeek has allowed us to focus on how we can take action by diagnosing and monitoring diabetes effectively. See below three tests run on the RX series for monitoring and diagnosing diabetes.
High levels of glucose present in the blood over a sustained period of time can end up damaging the blood vessels. Glucose comes from carbohydrate foods and it is the main source of energy used by the body. Insulin is a hormone that helps your body’s cells use the glucose and helps ensure levels don’t rise too high.
HbA1c is a very common test used indicating the blood glucose levels for the previous two to three months. HbA1c levels are directly correlated with increased risk of diabetes related deaths, making HbA1c tests vital.
Fructosamine testing enables an accurate review of a person’s average blood glucose level, and therefore diabetic status over a period of 2-3 weeks. Fructosamine testing is required for medication changes, gestational diabetes, red blood cell concerns and comorbidities.
If you would like to educate yourself more on Diabetes, including the diagnosis and monitoring, complications monitoring and associated biomarkers visit our website. We also have a full test menu available here.
Check out www.diabetes.org.uk for ways in which you can be a part of Diabetes Awareness Week this 2017!
Don’t forget to keep posted on our social media accounts for more educational information all week, remember use the hashtags to join in! #KnowDiabetes #DiabetesWeek #FightDiabetes
Randox Laboratories oferuje kompleksowe rozwiązania w zakresie testów lipidowych i kardiologicznych. Wysokiej wydajności odczynniki do wykrywania standardowych czynników ryzyka i odczynniki wskazujące biomarkery, powiązane z podwyższonym ryzykiem w połączeniu z ofertą kontroli jakości obejmującą szeroki zakres markerów kardiologicznych oraz lipidów na istotnym klinicznie poziomie, co tworzy zróżnicowany produkt, który spełnia wymagania każdego laboratorium.
Odczynniki firmy Randox do testów kardiologicznych i lipidowych
W obliczu potrzeby prowadzenia bardziej rozbudowanej analizy profilu lipidowego, w celu dokładniejszej oceny ryzyka zapadalności na choroby układu krążenia, zarówno w przypadku najczęściej ocenianych jak i mniej popularnych czynników ryzyka, pojawiło się zapotrzebowanie na narzędzia umożliwiające identyfikację oraz redukcję ryzyka. Firma Randox oferuje złożony produkt, którego profil kardiologiczny obejmuje zarówno wysokoprzepustowe odczynniki służące detekcji najczęściej testowanych czynników ryzyka jak i odczynniki do badania biomarkerów związanych z oceną późniejszej zapadalności na chorobę.
|Monitorowanie oceny ryzyka|
|Cholesterol HDL||Apolipoproteina C-II|
|Cholesterol LDL||Apolipoproteina C-III|
|Cholesterol całkowity||Apolipoproteina E|
|Niskocząsteczkowy cholesterol sLDL||sPLA2-IIA|
|Apolipoproteina A-I||Wysokoczuły CRP|
|Diagnoza zawału mieśnia sercowego|
|Typ sercowy białka wiążącego kwasy tłuszczowe (H-FABP)||Mioglobina|
Kontrola jakości Acusera do lipidów
Kontrola jakości Acusera do lipidów jest wytwarzana w 100% z ludzkiej surowicy w celu zapewnienia, najbardziej zbliżonego materiału do próbek pacjentów. Jak wszystkie nasze kontrole lipidowe są liofilizowane, nie zawierają one żadnych stabilizatorów ani konserwantów, które mogą mieć wpływ na ogólną wydajność kontroli. Kontrole Lipidowe, wieloparameterowe, odpowiednio skonsolidowane mają czteroletni okres trwałości materiału od daty produkcji co gwarantuje optymalizację kosztów w laboratorium.
Płynna kontrola lipidowa Acusera
Złożona kontrola zaprojektowana do stosowania w rutynowym monitorowaniu dokładności i precyzji. Wartości mianowane i zakresy przypisane są do poszczególnych analizatorów (biochemicznych, immunologicznych i POCT) dla 8 markerów kardiologicznych.
Wygodna forma płynna kontroli, gotowa do użycia od razu skraca czas przygotowywania a stabilność próbki 30 dni po otwarciu dla wszystkich parametrów minimalizuje ilość odpadów oraz redukuje koszty. Dostępne są 3 poziomy kontroli pokrywające cały zakres badań, co pozwala ma wiarygodną ocenę wydajności oraz podejmowanie właściwych decyzji.
W celu uzyskania dalszych informacji na temat zakresu testów kontroli lipidowych zapraszamy na stronę https://www.randox.com/liquid-cardiac-quality-control/ lub prosimy o kontakt pod adresem firstname.lastname@example.org
Randox celebrates British Science Week 2017
Last week was British Science Week 2017, an annual campaign that aims to inspire innovation and celebrate science. To mark the occasion, Randox Laboratories got involved by celebrating the innovation of each Randox product group. The product groups within Randox shared a series of posts, videos and blogs showcasing the #ScienceBehindRandox throughout British Science Week.
To initiate the Randox British Science Week campaign, Randox shared this video, which highlights the company’s dedication to improving health worldwide. The video provides an introduction about each product group, however throughout British Science Week, each product group has gone into further detail about the #ScienceBehindRandox.
Randox Careers, the RX series, Randox Reagents, Randox Quality Control, Randox Toxicology, Randox Biosciences, Randox Testing Services, & Randox Food Diagnostics all got involved in the British Science Week Campaign. You can read a snippet of each product groups post below, with videos and links to the full content also provided. We hope you enjoy learning about the #ScienceBehindRandox.
Randox – Dedicated to improving health wordwide.
Joanne Darragh spent some time with Randox Careers to discuss her role as R&D Toxicology Manager.
“Working in this area has been both challenging and exciting as we are at the cutting edge of assay development. We work in a great team and we work along very closely alongside other departments such as Marketing & Sales so that we are in close contact with what the customer needs, which means we are producing relevant tests very quickly and effectively. Every day brings a new challenge.”
– Joanne Darragh, R&D Toxicology Manager
Listen to what Joanne had to say on the video above
Randox RX series
As part of British Science Week, the RX series caught up with Daniel Melly, one of our very talented Mechanical Design Engineers based in Randox Teoranta in Dungloe, Ireland.
Daniel was an integral part of the team involved in the design of our new semi-automated analyser, the RX misano. The RX series asked Daniel a few questions about why Randox created this analyser, the design process involved in creating such a unique system, and what his favourite features are.
“Randox set out in creating the RX misano with the philosophy of supplying the customer with a more modern, reliable, and aesthetically pleasing analyser than those that are currently available on the market. Robust part selection was always at the fore of any design decisions, and we feel that we have delivered on all of these requirements.”
– Daniel Melly, Randox Mechanical Design Engineer
One unique test by Randox, adiponectin, is becoming an increasingly significant biomarker for health professionals. Low levels have been linked with several illnesses including metabolic syndrome, cancer and cardiovascular disease.
What is adiponectin?
Adiponectin is a protein hormone produced and secreted by fat cells called adipose tissue. Adiponectin is normally found in relatively high concentrations in healthy individuals. Its role in the body is to regulate the metabolism of lipids and glucose, which influences the body’s response to insulin and inflammation.
At Randox, our R&D Scientists are helping to change healthcare. By investing heavily into research and development to develop unique diagnostics tests, such as the adiponectin test, Randox provide doctors with the ability to identify disease risk sooner- offering the opportunity to prevent illness, rather than the need to find a cure.
Randox Quality Control
One Simple Change to Randox Quality Control can save your laboratory time and money.
Randox Quality Control are a world leading manufacturer of true third party controls with over 390 analytes covering Antioxidants, Blood Gas, Cardiac Markers, Routine Chemistry, Coagulation, Haematology, Diabetes, Immunoassay, Immunology, Lipids, POCT, Therapeutic Drugs, Toxicology and Urine Chemistry, providing complete test menu consolidation. Randox Quality Control produces the most consistent material available with the most accurate target values.
Randox Quality Control guarantee to simplify QC practice in any laboratory, just ask one of their 60,000 users worldwide.
Find out more information about Randox Quality Control in the video above
Randox Toxicology provides trusted solutions for the screening for drugs of abuse. With significant reinvestment in Research and Development, we persistently stay ahead of this ever challenging market. Being the first to develop New Psychoactive Substances tests such as fentanyl, bath salts and flakka allows us to maintain our position as a global leader.
Our pioneering technology has created a number of advancements in the field of toxicology. In particular, our patented Biochip Array Technology which can simultaneously screen from a multi-analyte testing platform, achieving a complete immunoassay profile from the initial screening phase.
During British Science Week, we are delighted to introduce you to our latest development utilising this technology; our Gastropanel Array,* a multiplex test engineered to diagnose those at risk of developing peptic ulcers and gastric cancer using non-invasive methods.
Our Gastropanel Array encompasses two quantitative assays, a H. pylori assay for the detection of antibodies produced in response to a H. pylori infection, a common cause of gastric cancer1 as well as a 3plex Gastropanel assay, for the detection of pepsinogen I (PGI), pepsinogen II (PGII) and gastrin 17 (G17).
Currently recorded as the world’s 5th most common cancer, the majority of gastric cancer cases are diagnosed after presenting as an emergency, when treatment may be less effective due to the cancer being at an advanced stage, highlighting the need for the availability of diagnostics tests like our Gastropanel Array to enable practitioners to administer prompt treatment and ultimately increase survival rates on a global scale.
Randox Testing Services
Randox Testing Services have shown how they are at the forefront of continually reacting and developing tests for NPS. NPS (formerley known as Legal Highs) have had devastating effects on users since emerging in the UK in 2008. These substances are highly dangerous and have caused unnecessary deaths. This is due to the effects from different elements used in production. Legislation concerning the substances changed in 2016 with the implementation of the Psychoactive Substance Act.
How have Randox Testing Services implemented change? Find out in the video above
Randox Food Diagnostics
Of the 41 antibiotics that are approved for use in food-producing animals by the FDA, 31 are medically important for human health. Randox Food Diagnostics provides advanced screening solutions for 94% of these antibiotics including beta-lactams, quinolones and tetracyclines, allowing you to ensure the integrity of your end product without compromising quality. Randox Food provides multiplex screening solutions validated across a range of matrices including urine, serum, tissue, milk, honey and feed.
The Evidence Investigator matched with Biochip Array Technology (BAT) provide the end user with fast, reliable results to aid in ensuring your produce is antibiotic free. BAT provides a platform for the simultaneous determination of multiple drug residues from a single sample using miniaturised immunoassays with implications in the reduction of sample/reagent consumption and an increase in the output of test results.
The use of ELISAs for clinical testing within a laboratory is notably time and personnel consuming, with heavy resources used on manual interaction. Moving from ELISA technique to an automated biochemistry method for detection of the same analyte increases time and personnel efficiency considerably – time and management efficiencies equal cost effectiveness. The significance of ensuring quality in testing practices, and as such confidence in clinical results, is also a key consideration for running automated biochemistry tests over manual ELISA testing techniques. The risk of error, contamination and therefore compromising clinical results (which is higher when running ELISA methods) will be greatly reduced through the alternative biochemistry automation.
By transitioning analytes historically only available on ELISA to automated biochemistry methods, laboratories are able to expand their test offerings to patients and clinicians. As an example within key cardiovascular testing, analysis such as H-FABP, 11dhTxB₂, adiponectin and sPLA₂ being available in an automated biochemistry format allows laboratories to expand their testing and test menu with ease. Automated biochemistry analytes increase testing range, with little adjustment within the laboratory, allowing for detailed patient testing profiles, without the manual restrictions placed by running ELISA techniques.
- Precision test detects minute deterioration in kidney function
- Identifies patients at early stages – missed by current testing
- NICE says new test regime could cut the number of patients on medication and dialysis by up to 20%
- Chronic kidney disease affects older people and more common in women
- Unchecked, CKD can eventually cause kidney failure and death
- CKD linked to diabetes, hypertension and cardiovascular disease
Millions of people in the UK are needlessly suffering from advanced kidney disease, because of a ‘blind spot’ in current testing methods. The traditional test used by the NHS to identify kidney dysfunction, measures the level of a waste product (Creatinine), which is only raised when up to 60% of the kidney has already been damaged. This damage is irreversible, with dialysis or transplant the only available therapies.
As kidney disease progresses, waste builds up in the blood which can have a significant impact on other key areas of the body; impairing heart health, weakening bones, reducing immune response and damaging the central nervous system. If left unchecked, CKD can cause kidney failure and death.
With early detection, the progression of CKD can be prevented; in response to this the National Institute for Health and Care Excellence, has drafted new guidance for doctors to improve diagnosis and identify kidney dysfunction in the earliest stages. The health watchdog makes it clear that a highly sensitive test for the biomarker Cystatin C, should be used alongside the traditional creatinine test, for more accurate and earlier identification of kidney function deterioration.
Cystatin C is a protein produced by the body at a constant rate, its small molecular weight allows it to be completely broken down and removed by the kidneys; levels therefore, remain steady if the kidneys are working efficiently and the glomerular filtration rate (GFR) is normal. If kidney function deteriorates, Cystatin C concentrations rise.
Testing for cystatin c means doctors can pick up on even the smallest changes in GFR, identifying a drop in kidney function at the earliest opportunity. Once a problem has been spotted early it can be managed through medication and/or changes to diet and lifestyle, preventing chronic kidney disease from occurring.
Around 2 million adults in England have CKD – but as it is largely asymptomatic and often undiagnosed, it is thought a further 1 million could also be suffering from the advanced stages of the disease. Dr Gilbert Wieringa, Consultant Biochemist at Bolton NHS Foundation Trust, a keen advocate of the test commented:
“I welcome the fact that NICE now recognises Cystatin C as a key biomarker in the differential diagnosis of CKD. The ready availability of this blood test ensures the right treatment can be started for the right patient in the right time in turn helping to prevent or delay progression of CKD, reducing or delaying complications, and reducing the risk of cardiovascular disease. It provides a key example where investment in a diagnostic test helps reduce far greater cost burdens of managing secondary complications further down the line”
NICE says that while using the cystatin c test will increase the cost of diagnosis “accuracy is expected to improve and fewer people are expected to require treatment and monitoring”.
Dr Peter FitzGerald, MD at UK Biotech firm Randox, which has created a cystatin C test for use in every standard hospital lab in the UK, believes the new diagnostic method could have a significant impact on the financial burden of CKD on the NHS:
“CKD is closely linked with diabetes, obesity, stoke and cardio vascular disease – as we see these conditions increase across the UK, so too will the prevalence of CKD, but if we can catch kidney function damage early, we can prevent CKD and prevent the need for expensive medical interventions such as dialysis, the cost of which per patient, per year is around £31,000. Needless to say, it also comes at considerable personal expense, but this does not have to be the way.”
NICE estimates that up to 20% of the current CKD population may not have needed medication, if the new testing method was introduced and says “savings are expected at a local level as a result of this change.”